Welcome to our dedicated page for Can-Fite BioPharma news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma stock.
Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced significant executive appointments aimed at advancing its commercialization efforts in psoriasis and liver cancer. Dr. Pnina Fishman has been appointed as Executive Chairman of the Board, maintaining her role as Chief Scientific Officer. Motti Farbstein, who has been with the company for 20 years, will take over as Chief Executive Officer while continuing his duties as Chief Financial Officer. These changes will be effective from June 30, 2023. The company is pushing forward with two pivotal Phase III trials for its drug candidates, Piclidenoson for psoriasis and Namodenoson for liver cancer. Can-Fite's prospects in the market are substantial, with ongoing evaluations and regulatory designations for its drugs, aimed at addressing major health conditions and tapping into multi-billion dollar markets.